Results 211 to 220 of about 451,760 (295)

Corrigendum: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. [PDF]

J Eur Acad Dermatol Venereol, 2020
Papadavid E, Scaribrick J, Ortiz Romero P, Quaglino P, Vermeer M, Knobler R, Stadler R, Bagot M.   +7 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, Volume 20, Issue 11, Page 2784-2804, November 2026.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea. [PDF]

Sci Rep
Moon IJ, Won CH, Chang SE, Park CS, Yoon DH, Song SY, Lee MW, Lee WJ.   +7 more
europepmc   +1 more source

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. [PDF]

Cancers (Basel), 2020
Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM.   +5 more
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3972-3981, November 2026.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

High Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Component C1q binding protein (C1QBP) is known as an important regulator of mitochondrial plasticity and is involved in antitumor immune response in cancers. Nevertheless, its role in lung adenocarcinoma (LUAD) still remains largely unknown.
Wei Li, Guangnan Huang, Lizhong Zeng, Wenhui Dang, Ting Jiao, Yonghong Zhang, Mengying Zhang, Shuru Zhou, Liping Chen, Shuanying Yang   +9 more
wiley   +1 more source

Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV‐1 Latency Reversal

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1414-1426, November 2026.
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Lauren A. R. Tompkins, Amanda Poliseno, Airlie Ward, Edward P. Browne, Cassandra Gilbert, Craig Sykes, Angela D. M. Kashuba, Mackenzie L. Cottrell   +7 more
wiley   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

MEF2A Promotes Keratinocyte Proliferation and Migration Under High‐Glucose Conditions via Activation of the PI3K/AKT Signaling Pathway: Implications for Diabetic Wound Healing

The Journal of Gene Medicine, Volume 28, Issue 11, November 2026.
MEF2A promotes keratinocyte function in diabetic wound healing by activating the PI3K/AKT signaling pathway. In vivo studies revealed an upregulation of MEF2A expression in the skin wound tissues of diabetic mouse models. In vitro functional experiments confirmed that under high‐glucose conditions, MEF2A overexpression activates the PI3K/AKT signaling ...
Yuan Xue, Min Xuan, Linlin Feng, Jingwen Kuang, Bin Xu, Limin Wei, Pengcheng Xu   +6 more
wiley   +1 more source